Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Study of AX-8 for Refractory Chronic Cough
2017-003108-27Phase 2Completed
- Sponsor
- Axalbion Therapeutics Limited
- Start
- Aug 2017
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of ax-8 in refractory chronic cough (RCC), sponsored by Axalbion Therapeutics Limited. Primary endpoint: Change from baseline in awake objective cough frequency after 1 dose of AX-8. Started Aug 2017; status: completed.
02
Drugs
ax-8
03
Conditions
refractory chronic cough (RCC)
Beyond the preview
Go deeper on 2017-003108-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003108-27.